Indication

Chronic heart failure

Chronic heart failure is a progressive clinical syndrome affecting the cardiovascular system, characterized by the persistent inability of the heart to maintain adequate cardiac output to meet systemic metabolic demands or doing so only at elevated ventricular filling pressures. Read more about Chronic heart failure

323 drugs 147 manufacturers

Advertisement

Drugs that treat it

Common Chronic heart failure therapies.

Showing 298–306 of 323 drugs

DAPAGLIFLOZIN

ANTIHYPERGLYCEMIC-SOD/GLUC COTRANSPORT-2 (SGLT2) INHIBITORS·TYPE 2 DIABETES MELLITUS·+4
MACLEODS PHARMA

DAPAGLIFLOZIN

ANTIHYPERGLYCEMIC-SOD/GLUC COTRANSPORT-2 (SGLT2) INHIBITORS·TYPE 2 DIABETES MELLITUS·+4
APOTEX CORP

DAPAGLIFLOZIN

ANTIHYPERGLYCEMIC-SOD/GLUC COTRANSPORT-2 (SGLT2) INHIBITORS·TYPE 2 DIABETES MELLITUS·+4
ALEMBIC PHARMAC

DAPAGLIFLOZIN

ANTIHYPERGLYCEMIC-SOD/GLUC COTRANSPORT-2 (SGLT2) INHIBITORS·TYPE 2 DIABETES MELLITUS·+4
AUROBINDO PHARM

DAPAGLIFLOZIN

ANTIHYPERGLYCEMIC-SOD/GLUC COTRANSPORT-2 (SGLT2) INHIBITORS·TYPE 2 DIABETES MELLITUS·+4
ASCEND LABORATO

DAPAGLIFLOZIN

ANTIHYPERGLYCEMIC-SOD/GLUC COTRANSPORT-2 (SGLT2) INHIBITORS·TYPE 2 DIABETES MELLITUS·+4
LUPIN PHARMACEU

DAPAGLIFLOZIN

ANTIHYPERGLYCEMIC-SOD/GLUC COTRANSPORT-2 (SGLT2) INHIBITORS·TYPE 2 DIABETES MELLITUS·+4
CIPLA USA, INC.

DAPAGLIFLOZIN

ANTIHYPERGLYCEMIC-SOD/GLUC COTRANSPORT-2 (SGLT2) INHIBITORS·TYPE 2 DIABETES MELLITUS·+4
ZYDUS PHARMACEU

DAPAGLIFLOZIN

ANTIHYPERGLYCEMIC-SOD/GLUC COTRANSPORT-2 (SGLT2) INHIBITORS·TYPE 2 DIABETES MELLITUS·+4
FLORIDA PHARMAC
Filter & compare in the drug finder →Opens the drug finder with Chronic heart failure preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Chronic heart failure.

Chronic heart failure is a progressive clinical syndrome affecting the cardiovascular system, characterized by the persistent inability of the heart to maintain adequate cardiac output to meet systemic metabolic demands or doing so only at elevated ventricular filling pressures.

Commonly arising secondary to conditions such as coronary artery disease, chronic hypertension, and cardiomyopathy, it primarily impacts adult and elderly populations.

Pathophysiologically, the disorder involves structural or functional impairment in ventricular filling (diastolic dysfunction) or myocardial ejection (systolic dysfunction), which triggers chronic neurohormonal activation, maladaptive cardiac remodeling, and systemic fluid retention.

Cardinal clinical features include exertional dyspnea, orthopnea, persistent fatigue, and signs of congestion such as peripheral edema and elevated jugular venous pressure.

Personalize your experience

Follow Chronic heart failure and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it